Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Verorab® in a One-week Intradermal Post-exposure Prophylaxis Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For all patients:~* Patient aged ≤50 years, with WHO category II or III contacts happened within 48 hours before appearance at site.~For adults:~* Informed consent form has been signed and dated.~* Able to attend all scheduled visits and to comply with all trial procedures.~For children:~* For children under 18 years of age, informed consent form has been signed and dated by the parent(s) or another legally acceptable representative.~* For children under 18 years, assent form or informed consent form has been signed and dated by the appropriate age-range patient, according to country specific institution requirement as detailed in each country specific assent form or informed consent form.~* Patient and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~For all patients:~* Receipt of chloroquine or other medications used for malaria chemoprophylaxis, with or without other anti-malarial treatment, for more than 4 weeks (duration of anti-malarial course) and part of the treatment received within the 2 weeks before vaccination.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial immunization~* Planned participation in another clinical trial during the present trial period~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza vaccination and tetanus immunization (related only to current animal bite exposure~* Planned receipt of any vaccine in the 4 weeks following the trial primary and booster vaccination~* Previous immunization against rabies at any time in the past with either the trial vaccine and immunoglobulin or another rabies immunobiological product (in pre-or post-exposure regimen)~* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)~* Self-reported seropositivity for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus~* Patient with clinical signs of encephalitis~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances~* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures~* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion~* Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator~* Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination~* Prior history of mammal animal bite within the past 5 years.~For infants or toddlers :~* Known personal or maternal seropositivity for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus, as reported by the parent/guardian~* Prior history of seizures .

- Gender: ALL
- Minimum Age: None
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Patients with WHO Category II exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen, and a single-visit, 4-site booster vaccination with PVRV 5 years later
- Group 2 (Type: EXPERIMENTAL): Patients with WHO Category III exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later
- Group 3 (Type: ACTIVE_COMPARATOR): Patients with WHO Category III exposure receive PEP with PVRV using the updated 2-site TRC (2-2-2-0-2) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete